Compare LQDA & CGAU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | CGAU |
|---|---|---|
| Founded | 2004 | 2002 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.9B |
| IPO Year | 2020 | 2021 |
| Metric | LQDA | CGAU |
|---|---|---|
| Price | $63.23 | $16.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 3 |
| Target Price | ★ $41.00 | $16.67 |
| AVG Volume (30 Days) | ★ 1.7M | 1.2M |
| Earning Date | 05-08-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.16% |
| EPS Growth | ★ 51.81 | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $158,320,000.00 | N/A |
| Revenue This Year | $278.87 | $25.17 |
| Revenue Next Year | $57.13 | $13.62 |
| P/E Ratio | $107.10 | ★ $11.74 |
| Revenue Growth | ★ 1031.18 | N/A |
| 52 Week Low | $11.85 | $6.71 |
| 52 Week High | $63.46 | $21.17 |
| Indicator | LQDA | CGAU |
|---|---|---|
| Relative Strength Index (RSI) | 67.44 | 45.22 |
| Support Level | $30.48 | $16.14 |
| Resistance Level | $63.46 | $19.95 |
| Average True Range (ATR) | 3.55 | 0.63 |
| MACD | -0.68 | 0.01 |
| Stochastic Oscillator | 74.24 | 44.68 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Centerra Gold Inc is principally focused on operating, developing, exploring and acquiring gold and copper properties in North America, Turkey, and other markets world-wide. The company reportable operating segments are Oksut; Mount Milligan; and Molybdenum. It derives maximum revenue from Mount Milligan segment. Geographically, it operates in Turkey, United States, and Canada.